elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Pricing
Log in
Sign up
Home
/
Subjects
/
Epidermal growth factor
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Epidermal growth factor
RIS
0.006
(Research Intensity Score)
Papers
1136
Top papers
Glioblastoma at the crossroads: current understanding and future therapeutic horizons
2025 · 225 citations
Notch signaling pathway in cancer: from mechanistic insights to targeted therapies
2024 · 367 citations
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
2023 · 234 citations
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer
2024 · 151 citations
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
2025 · 77 citations
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
2025 · 76 citations
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
2021 · 935 citations
Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
2021 · 640 citations
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
2021 · 677 citations
Newest papers
Partially Phosphidated Prussian Blue Analogues Derived Heterostructure Nanozyme for Colorimetric-Photothermal Dual-Mode Immunoassay
2026 · 12 citations
Glioblastoma at the crossroads: current understanding and future therapeutic horizons
2025 · 225 citations
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
2025 · 77 citations
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
2025 · 76 citations
Neoadjuvant Osimertinib for Resectable EGFR -Mutated Non–Small Cell Lung Cancer
2025 · 74 citations
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
2025 · 59 citations
Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives
2025 · 64 citations
Surface Functionalization of Nanocarriers with Anti-EGFR Ligands for Cancer Active Targeting
2025 · 57 citations
Sacituzumab tirumotecan versus docetaxel for previously treated EGFR -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial
2025 · 42 citations
Browse all papers →
Epidermal growth factor's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Epidermal growth factor's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link